ArticleInflammation2017
Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity.
Article in Inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 53 citations in OpenAlex.
- The relationship between obesity and disease relapse in systemic lupus erythematosus: a retrospective cohort study using the LUNA registry.Frontiers in immunology · 2026Article
- Body weight in systemic lupus erythematosus is associated with disease activity and the adaptive immune system, independent of type I IFN.Frontiers in immunology · 2025Article
- Review
- Review
- The interplay of aging, adipose tissue, and COVID-19: a potent alliance with implications for health.GeroScience · 2024Review
- Review
- The mechanisms of milder clinical symptoms of COVID-19 in children compared to adults.Italian journal of pediatrics · 2024Review
- Obesity dysregulates the pulmonary antiviral immune response.Nature communications · 2023Article
- Review
- Lung Epithelial Cells from Obese Patients Have Impaired Control of SARS-CoV-2 Infection.International journal of molecular sciences · 2023Article
- SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients.Frontiers in immunology · 2023Article
- Correlation between Type I Interferon Associated Factors and COVID-19 Severity.International journal of molecular sciences · 2022Review
- A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients.Cell communication and signaling : CCS · 2022Article
- Reviving the mutual impact of SARS-COV-2 and obesity on patients: From morbidity to mortality.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Mechanisms contributing to adverse outcomes of COVID-19 in obesity.Molecular and cellular biochemistry · 2022Review
- Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19.Nutrients · 2022Review
- Immune response to arbovirus infection in obesity.Frontiers in immunology · 2022Review
- The immunopathogenesis of SARS-CoV-2 infection in children: diagnostics, treatment and prevention.Clinical & translational immunology · 2022Review
- Review
- Innate-Immunity Genes in Obesity.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity provokes an imbalance in the immune system, including an aberrant type I interferon response during some viral infections and after TLR stimulation. SOCS3 overexpression and altered systemic leptin levels could be responsible for the reduced type I interferon production in people with obesity and, eventually, significantly increase the risk of viral infection. The aim of this study was to determine whether SOCS3- and leptin-induced tolerance are responsible for the reduced type I interferon production in people with obesity. SOCS3 overexpression in PBMCs from people with obesity was inhibited with the small interfering RNA (siRNA) assay, and leptin-induced tolerance was evaluated in PBMCs from non-obese volunte\ers and U937 cells treated with TLR ligands. SOCS3, but not SOCS1, gene silencing via siRNA increased the type I interferon response in PBMCs obtained from people with obesity. On the other hand, leptin induced SOCS3 expression and inhibited type I interferons in PBMCs from healthy donors and in U937 monocytes stimulated with TLR ligands. Taken together, these results demonstrate that reduced type I interferon production in obesity is caused by SOCS3 overexpression as well as tolerance induced by leptin. Here, we demonstrate a key role of leptin and SOCS3 in inhibiting the type I interferon response during obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.